Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

SZSE:301246 Stock Report

Market Cap: CN¥6.6b

Hubei Hongyuan Pharmaceutical Technology Valuation

Is 301246 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301246 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301246 (CN¥15.29) is trading above our estimate of fair value (CN¥1.26)

Significantly Below Fair Value: 301246 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301246?

Key metric: As 301246 is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 301246. This is calculated by dividing 301246's market cap by their current revenue.
What is 301246's PS Ratio?
PS Ratio3.3x
SalesCN¥1.82b
Market CapCN¥6.55b

Price to Sales Ratio vs Peers

How does 301246's PS Ratio compare to its peers?

The above table shows the PS ratio for 301246 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average3.6x
000411 Zhejiang Int'l GroupLtd
0.2xn/aCN¥5.7b
300194 Fuan Pharmaceutical (Group)
2.1xn/aCN¥6.0b
688513 Chengdu Easton Biopharmaceuticals
4.3x22.4%CN¥5.9b
301263 Guangdong Taienkang Pharmaceutical
7.7x24.5%CN¥6.0b
301246 Hubei Hongyuan Pharmaceutical Technology
3.3xn/aCN¥6.6b

Price-To-Sales vs Peers: 301246 is good value based on its Price-To-Sales Ratio (3.3x) compared to the peer average (3.6x).


Price to Sales Ratio vs Industry

How does 301246's PS Ratio compare vs other companies in the CN Pharmaceuticals Industry?

6 CompaniesPrice / SalesEstimated GrowthMarket Cap
600664 Harbin Pharmaceutical Group
0.6xn/aUS$1.34b
000411 Zhejiang Int'l GroupLtd
0.2xn/aUS$788.21m
000153 Anhui Fengyuan Pharmaceutical
0.7xn/aUS$418.19m
600781 FUREN Group PharmaceuticalLtd
0.3xn/aUS$66.91m
301246 3.3xIndustry Avg. 3.7xNo. of Companies35PS02.85.68.411.214+
6 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 301246 is good value based on its Price-To-Sales Ratio (3.3x) compared to the CN Pharmaceuticals industry average (3.7x).


Price to Sales Ratio vs Fair Ratio

What is 301246's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301246 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 301246's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies